C12N 2310/3235
Having the o of the ribose replaced by another atom
Official title: having the O of the ribose replaced by another atom
C12N2310/3235 (Having the o of the ribose replaced by another atom) appears on 6 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 17
- Assignees
- 11
- Inventors
- 37
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 6 |
| 2024 | 1 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- 5′-modified carbocyclic ribonucleotide derivatives and methods of use26 May 2026US 12,636,301 B2Sanegene Bio USA Inc.
- Engineered guide RNA and uses thereof15 Apr 2025US 12,275,951 B2Ohio State Innovation Foundation
- Complement component C3 iRNA compositions and methods of use thereof9 Jan 2024US 11,866,701 B2Alnylam Pharmaceuticals, Inc.
- siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene25 Aug 2020US 10,752,896 B2Sylentis S.A.U.
- Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom31 Jul 2018US 10,036,019 B2Ionis Pharmaceuticals, Inc.
- Complement component c3 irna compositions and methods of use thereof13 Aug 2026US 2026/0234623 A1Alnylam Pharmaceuticals, Inc.
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Synthetase (ASS1)16 Jul 2026US 2026/0201388 A1Korro Bio, Inc.
- Carbocyclic nucleoside, oligonucleotide and preparation methods therefor and medical uses thereof17 Jul 2025US 2025/0230146 A1Redfield Biotech Limited
- Complement component c3 irna compositions and methods of use thereof5 Sep 2024US 2024/0294912 A1Alnylam Pharmaceuticals, Inc.
- 5'-modified carbocyclic ribonucleotide derivatives and methods of use2 Nov 2023US 2023/0346819 A1Sanegene Bio USA Inc.
Most cited
By later US patents
- Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom3US 10,036,019 B2Ionis Pharmaceuticals, Inc. · 2018
- Oligonucleotide derivative, oligonucleotide derivative-containing pharmaceutical composition for treatment and pharmaceutical composition for diagnosis, and oligonucleotide derivative for regulation of miRNA function3US 9,315,810 B2National University Corporation Hokkaido University · 2016
- Complement component C3 iRNA compositions and methods of use thereof2US 11,866,701 B2Alnylam Pharmaceuticals, Inc. · 2024